Alex Rodriguez TRT: Photographic Before/After Analysis and Clinical Context

What the Photographs Actually Show Across Rodriguez's Career

Photographic evidence from Rodriguez's career spans three visually distinct phases: his lean Seattle Mariners debut (1994 to 2000), his Texas Rangers years with the admitted testosterone use (2001 to 2003), and his longer New York Yankees tenure (2004 to 2016), which itself breaks into a pre-Biogenesis period and the post-suspension decline phase.

Phase 1: Seattle Mariners (1994 to 2000)

Rodriguez broke into the majors at age 18. Early photographs show a tall, ectomorphic frame with low subcutaneous fat and modest upper-body mass, consistent with a naturally gifted adolescent athlete still maturing. His weight was reportedly around 195 to 200 lbs during this period.

Phase 2: Texas Rangers and Admitted Testosterone Use (2001 to 2003)

The most striking photographic shift coincides precisely with his move to Texas. Upper-body mass increased visibly, shoulder cap definition became more prominent, and facial structure appeared fuller, particularly through the jaw and cheeks, a change consistent with documented water retention and anabolic effects of testosterone. MLB photographs from 2002 to 2003 show considerably more trapezius and deltoid bulk compared with his 1999 All-Star appearance.

This matters clinically because exogenous testosterone, even at doses above physiologic range, produces predictable body-composition changes. The landmark Bhasin et al. Dose-response trial published in the New England Journal of Medicine demonstrated that 600 mg/week of testosterone enanthate for 10 weeks increased fat-free mass by 6.1 kg and reduced fat mass by 1.0 kg in healthy men, compared with 1.9 kg fat-free mass gain in the exercise-only group 1.

Phase 3: Yankees Era and Biogenesis (2004 to 2016)

Rodriguez's Yankees photographs from 2004 to 2012 show sustained mass and definition. Post-Biogenesis suspension (2014) and into his 2016 retirement, photographs document visible decreases in upper-body mass and increased facial leanness, a trajectory consistent with cessation of exogenous androgens and natural age-related testosterone decline.

What Alex Rodriguez Said and What MLB Found

Rodriguez's public statements are the only primary record available. In a February 2009 interview with ESPN's Peter Gammons, he stated: "I did take a banned substance. And for that, I am very sorry and deeply regretful." He named the substance as a banned stimulant/steroid combination he claimed he obtained in the Dominican Republic between 2001 and 2003.

The Biogenesis case in 2013 added a second documented exposure. MLB alleged Rodriguez received testosterone, human growth hormone (hGH), and IGF-1 analogs from Anthony Bosch's Coral Gables clinic. The 162-game suspension, upheld by arbitrator Fredric Horowitz in January 2014, rested on evidence including text messages, handwritten notes from Bosch's records, and witness testimony.

From a regulatory standpoint, testosterone is classified as a Schedule III controlled substance under 21 U.S.C. § 812, a classification confirmed and reinforced by the Anabolic Steroid Control Act of 2004 2.

How TRT Changes Physique: The Clinical Evidence

Understanding what Rodriguez's photographs likely reflect requires a clear picture of what testosterone does at physiologic versus supraphysiologic doses.

Physiologic Replacement (TRT)

Standard TRT, defined by the Endocrine Society as achieving serum total testosterone of 400 to 700 ng/dL in hypogonadal men, typically produces modest body-composition improvements over months, not weeks 3. A 2013 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,083 men) found TRT reduced fat mass by 1.6 kg and increased lean mass by 1.6 kg on average 4.

Endocrine Society Clinical Practice Guidelines specify: "We suggest that clinicians measure serum testosterone levels 3 to 6 months after initiating testosterone therapy to ensure levels are in the normal range." 3.

Supraphysiologic Dosing

The photographic changes seen in Rodriguez's Rangers-era images are more consistent with supraphysiologic dosing. The Bhasin dose-response study showed a near-linear relationship between testosterone dose and fat-free mass gain, with 600 mg/week producing 6.1 kg of lean mass in 10 weeks without any structured resistance training 1. Baseball players undergoing structured training during the same period would be expected to show even more pronounced changes.

Supraphysiologic testosterone also produces secondary visual markers: increased skin oiliness, more prominent venous definition, gynecomastia risk due to aromatization, and facial rounding from water retention. At least two of these, venous definition and facial fullness, are apparent across Rodriguez's authenticated photographs from 2001 to 2003.

IGF-1 and Growth Hormone Co-Administration

The Biogenesis allegations included IGF-1 and hGH. These compounds compound lean mass gains when added to a testosterone base. A Cochrane systematic review of hGH in athletes found it increased lean body mass by 2.1 kg over placebo but showed no strength benefit, suggesting its role is primarily cosmetic mass gain and recovery acceleration 5.

The Biogenesis Timeline and Suspension Evidence

Anthony Bosch operated the Biogenesis of America clinic in Coral Gables, Florida. The Miami New Times first published leaked records in January 2013. MLB retained private investigators and eventually reached a settlement with Bosch, who became a cooperating witness.

Rodriguez was the highest-profile of the 14 players suspended in August 2013. The others accepted 50-game penalties. Rodriguez initially appealed, continuing to play through the 2013 postseason before arbitrator Horowitz reduced his penalty from 211 games to 162 games in January 2014.

The arbitration decision is a matter of public record. Horowitz wrote that the evidence "established that Rodriguez received prohibited performance-enhancing substances" from Bosch during the 2010, 2011, and 2012 seasons.

From a pharmacological standpoint, testosterone cypionate has a half-life of approximately 8 days, meaning it clears to undetectable serum levels within 6 to 8 half-lives (roughly 48 to 64 days) without continued administration 6. The photographic documentation of Rodriguez's physique through the 2012 season is consistent with continued exogenous testosterone, while the 2015 to 2016 photographs show the muscle-mass attrition typical of testosterone cessation in a man then aged 39 to 41.

Distinguishing Natural Athletic Aging from PED Cessation

Separating age-related testosterone decline from cessation of exogenous androgens is clinically difficult from photographs alone, but the timeline is informative.

Normal Male Testosterone Decline

Total testosterone in healthy men declines roughly 1 to 2% per year after age 30 7. By age 40, many men are in the lower-normal range. Rodriguez was 38 when the 2013 allegations surfaced.

What Cessation Looks Like

When exogenous testosterone is withdrawn, endogenous hypothalamic-pituitary-gonadal (HPG) axis suppression resolves over weeks to months. Recovery timelines vary by duration and dose of prior use. A study in the Journal of Clinical Endocrinology and Metabolism found that HPG axis recovery took a median of 3.6 months after cessation of supraphysiologic testosterone, with full recovery in 91% of men by 12 months 8.

During HPG recovery, endogenous testosterone production is below baseline. This produces the lean-mass loss, increased fatigue, and reduced workout recovery that often appear in post-suspension athlete photographs. Rodriguez's 2015 Yankees photographs, taken after his return from suspension, show reduced muscle mass compared with 2009 to 2012.

Clomiphene and hCG as Recovery Agents

Some athletes use clomiphene citrate (50 mg/day) or human chorionic gonadotropin (hCG, 500 to 2,000 IU three times per week) to accelerate HPG recovery after a cycle. These protocols are documented in the clinical literature on hypogonadism management 9. Whether Rodriguez used any such protocol is not a matter of public record.

TRT in Professional Baseball: The Therapeutic Use Exemption Field

MLB introduced drug testing in 2003 and has operated under the Joint Drug Prevention and Treatment Program since that year. Testosterone is prohibited under this program, with one exception: players may apply for a Therapeutic Use Exemption (TUE) based on documented hypogonadism.

The number of TUEs granted in MLB has fluctuated. The TUE process requires clinical documentation of serum total testosterone below 300 ng/dL on two fasting morning measurements, consistent with Endocrine Society diagnostic criteria 3. An exempted player may then use testosterone at physiologic replacement doses only, targeting the mid-normal range of 400 to 700 ng/dL.

Critics have noted that TUE applications from professional athletes increased substantially after testing programs began, raising questions about whether hypogonadism diagnoses were being sought opportunistically. The FDA has separately warned that testosterone products are approved only for men with low testosterone due to a disorder of the testicles, pituitary gland, or brain, not for improving athletic performance or cosmetic muscle gain 2.

Health Risks of Supraphysiologic Testosterone: What Rodriguez's Case Illustrates

Rodriguez's case is a useful PED case study because the timeline is well-documented and the substances named (testosterone, hGH, IGF-1) each carry distinct risk profiles.

Cardiovascular Risk

Supraphysiologic testosterone suppresses HDL cholesterol significantly. The Bhasin dose-response trial found 600 mg/week reduced HDL by 21% 1. A 2023 analysis in JAMA Cardiology of TRT trials found no increased major adverse cardiovascular events at physiologic doses, but the authors noted this finding does not apply to the doses used by athletes, which are often 5 to 10 times the therapeutic range 10.

Hepatotoxicity

Injectable testosterone esters (cypionate, enanthate) carry minimal hepatic risk compared with oral 17-alpha-alkylated androgens. Rodriguez's alleged injectable testosterone would not typically raise liver enzymes at any dose, though concurrent hGH use does alter IGF-1-mediated hepatic signaling 5.

Polycythemia

Testosterone stimulates erythropoiesis. Supraphysiologic doses can raise hematocrit above 52%, increasing blood viscosity and stroke risk. Endocrine Society guidelines recommend withholding TRT if hematocrit exceeds 54% 3.

Testicular Atrophy and Fertility

Prolonged exogenous testosterone suppresses LH and FSH, leading to testicular atrophy and azoospermia. This is reversible in most men within 12 months of cessation 8.

Reading the Photographic Evidence: A Clinical Framework

Journalists and commentators often attribute athlete physique changes to PEDs based on aesthetic impression alone. A more rigorous approach matches observable changes to the pharmacology of the suspected compound, the timeline of alleged use, and known age and training confounders.

For Rodriguez, four observations converge:

1. The most pronounced upper-body mass increase coincides with his own admitted use period (2001 to 2003).
2. A secondary mass and recovery period (2010 to 2012) coincides with the Biogenesis-alleged period.
3. Physical decline accelerated after the 2014 suspension, faster than expected from natural aging alone.
4. The substances named (testosterone, hGH, IGF-1) produce exactly the visual markers present in the photographs: increased muscle cross-section, facial fullness, and vascular prominence.

None of this constitutes proof beyond what Rodriguez himself admitted and what arbitration determined. What it does show is that photographic before/after analysis, when anchored to pharmacokinetics and documented clinical data, is more than speculation. It is a data-informed framework.